“…Currently available evidence indicates the incidence of morbidity and mortality is high among HCC and IHCC patients treated using ALPPS [ 26 , 27 , 38 , 49 , 50 , 52 , 54 , 57 , 58 , 69 , 70 ]. In the first edition of the ALPPS World Registry [ 37 ], the 90-day mortality was reported to be 9%, but it was higher for HCC (12%), IHCC (13%), perihiliar cholangiocarcinoma (27%) and gallbladder carcinoma (33%) than in cases of colorectal liver metastasis (CRLM) (8%).…”